[79]
However, contrary to Abbott's assertions, Novopharm points out that Prothonotary Milczynski specifically found that there was evidence to support the inclusion of certain documents and information in the Protective Order. At page 9 of her May 6th Order, Prothonotary Milczynski states as follows:
"Novopharm has not established to my satisfaction that all of the material in the ANDS should be treated as confidential,
the only exceptions being information about the comparative bioequivalence of Novopharm's lansoprazole 15 mg and 30 mg delayed-release capsules, and the specific formulation of the capsules'non-medicinal ingredients, exceptions that appeared to be acknowledged (if not conceded) by the Applicants
." (Emphasis added)